Literature DB >> 11374675

Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up.

P Bytzer1, P S Teglbjaerg.   

Abstract

OBJECTIVE: The proportion of Helicobacter pylori-negative duodenal ulcer disease appears to be increasing. Data on clinical outcome and prognosis in this subgroup are lacking.
METHODS: Two hundred seventy-six duodenal ulcer patients randomized, irrespective of H. pylori status, to either eradication therapy or maintenance omeprazole (double-blind, double-dummy design) for 1 yr were studied. Patients were followed up for a total of 2 yr, with visits performed every 2 months the first year and every 6 months the following year. Endoscopies for assessment of ulcer relapse were done at 6 and 12 months or in the event of symptomatic relapse. H. pylori status was assessed by culture, immunohistochemistry, and urea breath test at entry, at 6, 12, and 24 months or at failure. The primary endpoint was discontinuation, irrespective of reason. Patients were considered H. pylori negative if all three tests were negative. Patients were considered H. pylori-positive if any of the three diagnostic tests were positive. Study staff were blinded to H. pylori results.
RESULTS: Thirty-two (12%) patients were H. pylori negative at entry. There were no differences according to H. pylori status for a number of clinical and demographic characteristics. However, H. pylori-negative patients had a shorter history of ulcer symptoms and were more likely to be NSAID users (19% vs 1%, p < 0.001). Only 28% of the H. pylori-negative patients completed the study, as compared with 40% of H. pylori-positive patients (p = 0.0005). The main reasons for the poorer prognosis in H. pylori-negative patients were relapse of ulcer/ulcer not healed (35% vs 26%) and relapse of severe dyspepsia symptoms without ulcer relapse (16% vs 7%). H. pylori-negative patients randomized to eradication therapy left the study early compared with H. pylori-negative patients randomized to long-term omeprazole therapy. Outcome in omeprazole-treated patients did not differ according to H. pylori status (p = 0.3).
CONCLUSIONS: Clinical characteristics in H. pylori-negative and positive duodenal ulcer patients differ little. Clinical outcome over 2 yr is significantly poorer in H. pylori-negative patients, especially if treated empirically with eradication therapy. These results suggest that H. pylori infection should be assessed in all duodenal ulcer patients before treatment is decided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374675     DOI: 10.1111/j.1572-0241.2001.03774.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  22 in total

1.  Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptic ulcers in India.

Authors:  Mahesh Kumar Goenka; Shounak Majumder; Pradeepta Kumar Sethy; Madhurima Chakraborty
Journal:  Indian J Gastroenterol       Date:  2011-03-22

Review 2.  Precise role of H pylori in duodenal ulceration.

Authors:  Michael Hobsley; Frank I Tovey; John Holton
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 3.  Role of dietary phospholipids and phytosterols in protection against peptic ulceration as shown by experiments on rats.

Authors:  Frank I Tovey
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

4.  Patients with Helicobacter pylori positive and negative duodenal ulcers have distinct clinical characteristics.

Authors:  Kent-Man Chu; Ka-Fai Kwok; Simon Law; Kam-Ho Wong
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

Review 5.  Giant duodenal ulcers.

Authors:  Eric Benjamin Newton; Mark R Versland; Thomas E Sepe
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

6.  Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.

Authors:  Kae Sugawara; Shigeto Koizumi; Yohei Horikawa; Nobuya Mimori; Tsuyotoshi Tsuji; Hajime Ishii; Shusei Fujimori; Kengo Onochi; Hiroyuki Watanabe; Katsunori Iijima
Journal:  J Gastroenterol       Date:  2019-04-29       Impact factor: 7.527

Review 7.  Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia.

Authors:  Katsunori Iijima; Takeshi Kanno; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 8.  Helicobacter pylori: friend or foe?

Authors:  Stephen David Howard Malnick; Ehud Melzer; Malka Attali; Gabriel Duek; Jacob Yahav
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Significance of an exaggerated meal-stimulated gastrin response in pathogenesis of Helicobacter pylori-negative duodenal ulcer.

Authors:  Tomoari Kamada; Ken Haruma; Hiroaki Kusunoki; Masaki Miyamoto; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Kazuaki Chayama; Kazumasa Tahara; Yuzuru Kawamura
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

10.  Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection.

Authors:  Hala El-Zimaity; Stefano Serra; Eva Szentgyorgyi; Rajkumar Vajpeyi; Amir Samani
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.